Sigyn Therapeutics, Inc. · OTC:SIGY
Sigyn Therapeutics — Investor Presentation (March 2025)
31 slides from Sigyn Therapeutics's investor presentation, Mar 7, 2025
Slide 1: Next-Generation Blood Purification Therapies
February 19, 2025 ae SIGYN THERAPEUTICS eS A po am f y g Growth = Jim Joyce CEO, Inventor
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS 4 tion is for informational purposes only and is not an offer to sell oF a solicitation of an offer to herapeutics, Inc. (“Sigyn"). All statements in this presentation, other than statements of -looking statements within the meaning of federal securities laws. In some case
Slide 3: Next-Generation Blood Purification Therapies
Next-Generation Blood Purification Therapies @®SIGYN THERAPEUTICS
Slide 4: Investment Considerations
Investment Considerations eS > Sigyn 7 \ 4 untreatable infectious disease ‘disorders — ge market comp to treat sepsis ~ 20% current Sigyn value _ - Pa TA, ROE ES RR epee Is company peaked at ~30x current Sigyn value - pe ic > Pipeline of a candic a ChemoPrep™ rformance of cancer therapies “6 sI8YN T
Slide 5: Sigyn Therapy
Sigyn Therapy™ To Address Life-Threatening Infections 1. Broadly Deployable 2. Highly Efficient 3. Immense Capacity 4. Broad Spectrum Mechanism First-in-Mammal Studies at University of Michigan THERAPEUTICS & SGN a
Slide 6: Broadly Deployable
Broadly Deployable Sigyn Therapy™ S S)NGYN THERAPEUTICS
Slide 7: Highly Efficient
Highly Efficient Sigyn Therapy™ S S)NGYN THERAPEUTICS
Slide 8: Immense Capacity
Immense Capacity Sigyn Therapy™ S S)NGYN THERAPEUTICS
Slide 9: Broad-Spectrum Mechanism
Broad-Spectrum Mechanism Sigyn Therapy™ S S)NGYN THERAPEUTICS
Slide 10: Leading Cause of Hospital Deaths
Leading Cause of Hospital Deaths Emerging Gj6bal “ie Threat Antibiotic- rat Neod™ ESRD Resistant in Global Health [ERR Rrercnarl Bacteria Sepsis Early Clinjcal Opportunity in Di: Most Viruses are not treatable wl Untreatable Viral Pathogens
Slide 11: Early Clinical & Commercialization Opportunity
EARLY CLINICAL & COMMERCIALIZATION OPPORTUNITY End-Stage Renal Disease (ESRD) Endotoxemia Vv 550,000+ dialysis dependent ESRD patients in the United States > ~20% annual mortality rate » Endotoxemia and concurrent inflammation underly early causes of death > Incidence of endotoxemia is 60-90% (>330,
Slide 12: Potential Value of Sigyn Therapy to the Dialysis Industry
Potential Value of Sigyn Therapy to the Dialysis Industry » Extending ESRD patient lives increases revenues > Provides pathway into non-ESRD markets
Slide 13: The Dialysis Industry is Dominated By Two Organizations
The Dialysis Industry is Dominated By Two Organizations in North America
Slide 14: ~200,000 ESRD Patients in North American Network
~200,000 ESRD patients in North American Network Average annual revenue per patient is ~$58,000 $960 million of increased revenue per month of extended ESRD patient life $240 million in recouped revenues per week of reduced hospitalization
Slide 15: ~208,000 ESRD Patients in North American Network
~208,000 ESRD patients in North American Network Average annual revenue per patient is ~$70,000 $1.2 billion of increased revenue per month of extended ESRD patient life $300 million in recouped revenues per week of reduced hospitalization
Slide 16: End-Stage Renal Disease (ESRD) Clinical Plan
End-Stage Renal Disease (ESRD) Clinical Plan » Investigation Device Exemption (IDE) drafted for FDA submission > Enrollment of 12-15 ESRD subjects with endotoxemia and concurrent inflammation at three site locations (Hartford, San Antonio, Las Vegas) >» Sigyn Therapy administered during regularly sc
Slide 17: About Sepsis
About Sepsis Vv Vv Vv Leading cause of death in U.S. hospitals” $38 billion annual cost to the U.S. healthcare system” A dysregulated immune response most often induced by a bacterial or viral infection An excessive production of pro-inflammatory cytokines (“the cytokine storm”) Bacterial toxins tha
Slide 18: Sigyn Therapy Sepsis Related Studies
Sigyn Therapy™ Sepsis Related Studies” >» Adysregulated immune response most often induced by a bacterial or viral infection The clearance of viral pathogens from human blood plasma has been validated Vv An excessive production of pro-inflammatory cytokines (“the cytokine storm”) The clearance of TN
Slide 19: Clinical-Stage Market Comparable to Treat Sepsis
Clinical-Stage Market Comparable to Treat Sepsis Spectral Medical holds the North American rights to the Polymyxin B (”PMX") endotoxin removal device PMX is being evaluated in a study of adults with endotoxemia and septic shock As a model for clinical progression-based value, Spectral Medical has a
Slide 20: Oncology
Slide 21: Chemotherapy
Chemotherapy >» Most common class of drug to treat cancer » < 3.5% is delivered to tumor-cell targets > Off-target chemotherapy contributes to toxicity >» Cancer cells release exosomes that interfere with chemotherapy delivery (chemosomes)
Slide 22: ChemoPrep and ChemoPure Devices
Associated with a pending patent e: |: “SYSTEMS AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND E TOXICITY" Therapeutic obj reduction) — By ’ 5 4 i ; Py j F ChemoPure™ H ’ ' > Post-treatment ance rapy to further mitigate treatment toxicity THERAPEUTICS G SISYN \ | | |
Slide 23: Immunotherapeutic Antibodies
Immunotherapeutic Antibodies > Top selling drugs to treat cancer >» Most valued assets in global medicine based On 2023 & 2024 M&A activity > Over 1000 human studies, yet no effective strategy to improve delivery
Slide 24: Limitation of Immunotherapeutic Antibodies
Limitation of Immunotherapeutic Antibodies “> > ~2% of doses reach intended cancer cell target > Delivery intercepted by circulating decoys that display the binding site receptor of the antibody i >» Most patients don’t respond to therapy J
Slide 25: Devices for Enhancing the Activity of Therapeutic Antibodies
Associated with a pending p: entitled: “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC IBODIES” orate a therapeutic antibody to sweep decoys from circulation pri e antibody into a cancer patient 7 a f the antibody’s therapeutic target to further enhance patient benefit without adde toxicit’ a, F
Slide 26: PP a clusiceh rrr oa bil
PP a clusiceh rrr oa bil — - i THERAPEUTICS \\\ Ve Ss IGYN I]
Slide 27: Next-Generation Blood Purification Therapies
Next-Generation Blood Purification Therapies @®SIGYN THERAPEUTICS
Slide 28: Summary
Summary » Lead product targets infectious disease disorders not treatable with drugs » Pipeline comprised of first-in-industry devices to improve delivery of leading cancer therapies “Sigyn Therapy in Action” G SISYN THERAPEUTICS 28
Slide 29: Public Market Data
Public Market Data OTCOB: SIGY 52-Week Range: $3.15 - $6.34 Shares Outstanding: 1,605,377 >90% of Shares Outstanding are held by management, two funds, and one investment group S SIGYN THERAPEUTICS
Slide 30: Reg D 506(c) Convertible Note Offering
mop npn cnet nt > 20250 (offering 75 million Reg D 506c offering of 10% convertible notes! ents now available) am 2 EE TE 2 pace mpany previously raised ~$5 mi average conversion price was $6. Company has submitted listing ap} assurance the any will achieve the listing requireme THERAPEUTICS G SISYN
Slide 31: Contact
6 | Gaya THERAPEUTICS Jim Joyce 2468 Historic Decatur Road, Suite 140 CEO, Inventor ; San Diego, California 92106 jj@sigyntherapeutics.com SigynTherapeutics.com 31
Sigyn Therapeutics — Investor Presentation (March 2025) on 6ix